Dr Chris Heery NCIDr Chris Heery (@ChrisHeery) is a medical oncologist at the National Cancer Institute (NCI) who works in the Laboratory of Tumor Immunology and Biology (LTIB) with Jeffrey Schlom, James Gulley and other translational scientists.

The aim of the LTIB is to develop novel immunotherapies for cancer. One of the ways this is accomplished is through a Cooperative Research and Development Agreement (CRADA), in essence a joint venture with the private sector.

At the recent Society for Immunotherapy of Cancer (SITC) annual meeting, Dr Heery presented a poster on the results of a phase 1 clinical trial to evaluate the safety and tolerability of a therapeutic vaccine, MVA-BN Brachyury, targeting brachyury. See Bavarian Nordic Press Release Nov 3, 2015.

We previously heard at ASCO 2015 about the rational for targeting brachyury from Dr James Gulley (see post: Future of Prostate Cancer Immunotherapy).

It was a pleasure to talk with Dr Heery about his poster and what the potential of therapeutic cancer vaccines may be in the cancer immunotherapy arsenal.

Subscribers can login to read more or you can purchase access below.

Posted by 

Purchase Access to Premium Content

PLEASE READ BEFORE YOU BUY. Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. Please READ our TERMS OF USE before purchasing (link at bottom of page): You are NOT PERMITTED to share access or copies of posts. If you work for a CONSULTING FIRM, AGENCY, or are in PR or COMMUNICATIONS you cannot purchase an INDIVIDUAL license through this site without prior approval (even if your use is personal) and typically a CORPORATE license will be required. Please CONTACT US to discuss how you might use our content & obtain a quote for the appropriate license. Rates may change without notice and are non-refundable. If you in any doubt about whether you can buy through the blue icon, PLEASE CONTACT US first.